Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal phase III trial of SPN-604 (Oxtellar XR) for Bipolar disorders

Next Previous
Trial Profile

A Pivotal phase III trial of SPN-604 (Oxtellar XR) for Bipolar disorders

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Bipolar disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Supernus Pharmaceuticals

    • Most Recent Events

    • 05 Nov 2019 According to Supernus Pharmaceuticals media release, this trial has been initiated in the fourth quarter of 2019.
    • 05 Nov 2019 Status changed from planning to recruiting, according to Supernus Pharmaceuticals media release.
    • 06 Aug 2019 According to Supernus Pharmaceuticals media release, trial is expected to start in the fourth quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top